Speaker Profile

Professor, Bioengineering, UC San Diego

Jeff Hasty engineers synthetic gene networks in order to gain insight into the general modules of gene regulation. These modules include subnetworks that act as switches or oscillators, as well as networks that communicate across a population of cells. The work provides a framework for predicting and evaluating basic gene regulatory motifs that govern protein production at the genomic level. Hasty develops and uses mathematical models to analyze gene networks and employs experimental techniques to construct the networks according to the model blueprint. For example, he has developed a model of a positive feedback loop, in which a gene produces a protein which in turn causes that gene to become more active. He has confirmed this model in experimental studies with E-coli. Hasty believes there are many such modular mechanisms that taken together, control the function of cells. Understanding genetic networks is a first step towards logically controlling and monitoring the function of cells. Hasty’s long-term goal is to build synthetic genetic switches or oscillators which could be inserted into a patient’s cells to tightly regulate the expression of a desired protein, or even to cause an undesirable cell to self-destruct. Hasty has been an invited speaker on gene regulatory networks at more than 20 professional meetings, and his work has been covered in the popular press including CNN and Business Week.

 Session Abstract – PMWC 2022 Silicon Valley

Understanding mechanism of action and translating microbiome science into commercially viable therapeutics remains the biggest challenge in this emerging field. With that said, pharma and biotech across many different therapeutic indications and modalities are united in this global effort to bring novel microbiome-based therapies and diagnostics into the clinical domain. This session will include some of the most impactful and promising areas of the Microbiome field and panel discussions on the challenges for faster adoption.


Microbiome and Cancer
Jennifer Wargo, MD Anderon
Sandrine Miller-Montgomery, Micronoma

The Gut/Brain Microbiome
Mary Conrad, Axial Biotherapeutics
Chris Reyes, Bloom Science
Rosa Krajmalnik-Brown, Arizona State University

The Role of the Human Gut Microbiome on Various Diseases
Colleen Cutcliffe, Pendulum Therapeutics
Tor Savidge, Baylor College of Medicine
Nikole Kimes, Siolta Therapeutics
Sarkis Mazmanian, Caltech

Pharma Drug Development
Karim Dabbagh, Second Genome
Ethan Grant, Gilead
Matthew Henn, Seres

Direct-To-Consumer Testing/Technologies
Kiran Krishnan, Microbiome Labs
Nathan Price, Onegevity
Nicole Scott, Cybele
Emmanuel Hanon, Viome

Regulatory Perspective
Scott Jackson, NIST

Synthetic Biology in Microbiome
Jeff Hasty, UCSD

AI & ML in Microbiome
Kaja Milanowska-Zabel, Ardigen